Bicara Therapeutics (BCAX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $16.78, -4.77% vs the prior close of $17.62.
- Volume 820.00K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BCAX slides 4.8% to $16.78. Closed at $16.78, -4.77% vs the prior close of $17.62. Day range $16.69–$17.60, opened at $17.60.
BCAX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BCAX slides 4.8% to $16.78
- Closed at $16.78, -4.77% vs the prior close of $17.62. Day range $16.69–$17.60, opened at $17.60.
- Volume was 820.00K shares, 1.2x its 50-day average of 697.95K.
- Price is -22.9% vs its 50-day average ($21.75) and -21.2% vs its 200-day average ($21.30).
- 52-week range $13.70–$30.99; today's close sits at 18% of that range, 45.9% below the 52-week high.
Oct 15, 2026 — BCAX rises 1.6% to $17.62
- Closed at $17.62, +1.61% vs the prior close of $17.34. Day range $17.25–$17.95, opened at $17.51.
- Volume was 662.10K shares, 0.9x its 50-day average of 701.08K.
- Price is -19.8% vs its 50-day average ($21.97) and -17.3% vs its 200-day average ($21.30).
- 52-week range $13.70–$30.99; today's close sits at 23% of that range, 43.1% below the 52-week high.
Oct 14, 2026 — BCAX ends flat (+0.0%) to $17.34 on 2.1x normal volume
- Closed at $17.34, +0.00% vs the prior close of $17.34. Day range $17.11–$17.68, opened at $17.23.
- Volume was 1.43M shares, 2.1x its 50-day average of 688.81K — unusually heavy trading.
- Price is -21.7% vs its 50-day average ($22.13) and -18.6% vs its 200-day average ($21.29).
- 52-week range $13.70–$30.99; today's close sits at 21% of that range, 44.0% below the 52-week high.
Oct 13, 2026 — BCAX ends flat (+0.1%) to $17.34 on 1.9x normal volume
- Closed at $17.34, +0.06% vs the prior close of $17.33. Day range $17.01–$17.61, opened at $17.29.
- Volume was 1.27M shares, 1.9x its 50-day average of 671.44K — unusually heavy trading.
- Price is -22.3% vs its 50-day average ($22.31) and -18.6% vs its 200-day average ($21.29).
- 52-week range $13.70–$30.99; today's close sits at 21% of that range, 44.0% below the 52-week high.
Oct 12, 2026 — BCAX dips 1.0% to $17.33
- Closed at $17.33, -0.97% vs the prior close of $17.50. Day range $17.11–$17.99, opened at $17.46.
- Volume was 659.10K shares, 1.0x its 50-day average of 672.06K.
- Price is -22.9% vs its 50-day average ($22.48) and -18.6% vs its 200-day average ($21.29).
- 52-week range $13.70–$30.99; today's close sits at 21% of that range, 44.1% below the 52-week high.
Oct 9, 2026 — BCAX rises 1.4% to $17.50
- Closed at $17.50, +1.39% vs the prior close of $17.26. Day range $16.88–$17.82, opened at $17.19.
- Volume was 716.00K shares, 1.1x its 50-day average of 674.27K.
- Price is -22.8% vs its 50-day average ($22.67) and -17.8% vs its 200-day average ($21.29).
- 52-week range $13.70–$30.99; today's close sits at 22% of that range, 43.5% below the 52-week high.
Oct 8, 2026 — BCAX jumps 5.1% to $17.26 on 1.9x normal volume
- Closed at $17.26, +5.12% vs the prior close of $16.42. Day range $15.85–$17.33, opened at $16.32.
- Volume was 1.25M shares, 1.9x its 50-day average of 659.39K — unusually heavy trading.
- Price is -24.5% vs its 50-day average ($22.85) and -18.9% vs its 200-day average ($21.29).
- 52-week range $13.70–$30.99; today's close sits at 21% of that range, 44.3% below the 52-week high.
Oct 7, 2026 — BCAX dips 0.8% to $16.42, a 6-month low, 5 down days in a row
- Closed at $16.42, -0.85% vs the prior close of $16.56. Day range $16.25–$17.11, opened at $16.44.
- Volume was 915.60K shares, 1.4x its 50-day average of 650.88K.
- Price is -28.7% vs its 50-day average ($23.02) and -22.9% vs its 200-day average ($21.30).
- 52-week range $13.70–$30.99; today's close sits at 16% of that range, 47.0% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — BCAX slides 4.2% to $16.56, a 6-month low, 4 down days in a row
- Closed at $16.56, -4.22% vs the prior close of $17.29. Day range $16.31–$17.52, opened at $17.43.
- Volume was 981.20K shares, 1.5x its 50-day average of 641.24K.
- Price is -28.7% vs its 50-day average ($23.23) and -22.3% vs its 200-day average ($21.30).
- 52-week range $13.70–$30.99; today's close sits at 17% of that range, 46.6% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — BCAX dips 1.9% to $17.29, a 6-month low, 3 down days in a row
- Closed at $17.29, -1.93% vs the prior close of $17.63. Day range $17.13–$19.12, opened at $17.63.
- Volume was 640.70K shares, 1.0x its 50-day average of 638.06K.
- Price is -26.3% vs its 50-day average ($23.46) and -18.9% vs its 200-day average ($21.31).
- 52-week range $13.70–$30.99; today's close sits at 21% of that range, 44.2% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — BCAX slides 3.1% to $17.63, a 6-month low
- Closed at $17.63, -3.13% vs the prior close of $18.20. Day range $17.56–$18.96, opened at $18.50.
- Volume was 763.10K shares, 1.2x its 50-day average of 629.95K.
- Price is -25.5% vs its 50-day average ($23.65) and -17.3% vs its 200-day average ($21.31).
- 52-week range $13.70–$30.99; today's close sits at 23% of that range, 43.1% below the 52-week high.
BCAX latest news & SEC filings
Every SEC filing by or about BCAX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cohlhepp Ryan sold 3,442 shares at $23.43 (≈$80.65K) on Sep 8, 2026
- Cohlhepp Ryan sold 14,058 shares at $22.77 (≈$320.10K) on Sep 8, 2026
- Cohlhepp Ryan sold 3,442 shares at $23.43 (≈$80.65K) on Sep 8, 2026
- Cohlhepp Ryan sold 14,058 shares at $22.77 (≈$320.10K) on Sep 8, 2026
- Cohlhepp Ryan sold 3,442 shares at $23.43 (≈$80.65K) on Sep 8, 2026
- Cohlhepp Ryan sold 14,058 shares at $22.77 (≈$320.10K) on Sep 8, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hyep Ivan sold 12,500 shares at $27.97 (≈$349.62K) on Aug 10, 2026
- Hyep Ivan sold 12,500 shares at $27.97 (≈$349.62K) on Aug 10, 2026
- Hyep Ivan sold 12,500 shares at $27.97 (≈$349.62K) on Aug 10, 2026
- Hyep Ivan sold 12,500 shares at $27.97 (≈$349.62K) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 11, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$55.44M (prior year -$27.39M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.82 (prior year -$0.50) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade BCAX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 30, 2026, Feb 26, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.63% (largest 10.1%).
- Liquidity: about 850.73K shares (≈$14.28M) trade per day on average.
- 52-week position: $16.78 vs a range of $13.70–$30.99 (18% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Ryan Cohlhepp sold 3,442 shares on Sep 8, 2026.
- Latest filings: 8-K Aug 25, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 66.17M shares outstanding (Aug 6, 2026), +21.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BCAX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 17.60 | 17.60 | 16.69 | 16.78 | 820.00K |
| Oct 15, 2026 | 17.51 | 17.95 | 17.25 | 17.62 | 662.10K |
| Oct 14, 2026 | 17.23 | 17.68 | 17.11 | 17.34 | 1.43M |
| Oct 13, 2026 | 17.29 | 17.61 | 17.01 | 17.34 | 1.27M |
| Oct 12, 2026 | 17.46 | 17.99 | 17.11 | 17.33 | 659.10K |
| Oct 9, 2026 | 17.19 | 17.82 | 16.88 | 17.50 | 716.00K |
| Oct 8, 2026 | 16.32 | 17.33 | 15.85 | 17.26 | 1.25M |
| Oct 7, 2026 | 16.44 | 17.11 | 16.25 | 16.42 | 915.60K |
| Oct 6, 2026 | 17.43 | 17.52 | 16.31 | 16.56 | 981.20K |
| Oct 5, 2026 | 17.63 | 19.12 | 17.13 | 17.29 | 640.70K |
| Oct 2, 2026 | 18.50 | 18.96 | 17.56 | 17.63 | 763.10K |
| Oct 1, 2026 | 18.61 | 19.23 | 18.12 | 18.20 | 698.00K |
| Sep 30, 2026 | 18.71 | 18.95 | 18.39 | 18.61 | 905.40K |
| Sep 29, 2026 | 18.88 | 19.39 | 18.51 | 18.56 | 599.80K |
| Sep 28, 2026 | 19.21 | 19.26 | 18.59 | 18.80 | 775.30K |
| Sep 25, 2026 | 19.86 | 19.89 | 19.17 | 19.21 | 662.50K |
| Sep 24, 2026 | 20.43 | 20.84 | 19.33 | 19.78 | 1.37M |
| Sep 23, 2026 | 22.78 | 23.11 | 20.48 | 20.49 | 954.80K |
| Sep 22, 2026 | 22.31 | 22.91 | 22.23 | 22.78 | 622.20K |
| Sep 21, 2026 | 23.06 | 23.34 | 21.95 | 22.01 | 315.40K |
About Bicara Therapeutics
Bicara Therapeutics (BCAX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2023658.
BCAX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeremy Bender | Director | Jul 29, 2026 |
| Christopher Bowden | Director | Jun 10, 2026 |
| Ryan Cohlhepp | President, COO & Interim CEO | Sep 10, 2026 |
| Kate Haviland | Director | Jun 10, 2026 |
| Peter Kolchinsky | Director | Jun 10, 2026 |
| Claire Mazumdar | Chief Executive Officer | Aug 12, 2026 |
| Kiran Mazumdar-Shaw | Director | Jun 10, 2026 |
| Christy J. Oliger | Director | Jul 29, 2026 |
| Michael Powell | Director | Jun 10, 2026 |
| Capital Management, L.P. Ra | Director | Jun 10, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Jun 10, 2026 |
| Capital Nexus Fund Iii, L.P. Ra | Director | Jun 10, 2026 |
| Scott M. Robertson | Director | Jun 10, 2026 |
| Rajeev M. Shah | Director | Jun 10, 2026 |
| Jake Simson | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ryan Cohlhepp | President, COO & Interim CEO | Sep 10, 2026 |
| Ivan Hyep | Chief Financial Officer | Aug 12, 2026 |
| Jennifer Larson | Chief Financial Officer | Aug 14, 2026 |
| Claire Mazumdar | Chief Executive Officer | Aug 12, 2026 |
| Lara Meisner | Chief Legal Officer | Feb 4, 2026 |
| David Raben | Chief Medical Officer | Apr 28, 2026 |
| William Schelman | Chief Medical Officer | May 12, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 3,442 | $23.43 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 14,058 | $22.77 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 3,442 | $23.43 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 14,058 | $22.77 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 3,442 | $23.43 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 14,058 | $22.77 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 3,442 | $23.43 |
| Sep 8, 2026 | Ryan Cohlhepp | Sale | 14,058 | $22.77 |
| Aug 10, 2026 | Claire Mazumdar | Sale | 10,000 | $27.98 |
| Aug 10, 2026 | Claire Mazumdar | Sale | 10,000 | $27.98 |
| Aug 10, 2026 | Claire Mazumdar | Sale | 10,000 | $27.98 |
| Aug 10, 2026 | Claire Mazumdar | Sale | 10,000 | $27.98 |
| Aug 10, 2026 | Ivan Hyep | Sale | 12,500 | $27.97 |
| Aug 10, 2026 | Ivan Hyep | Sale | 12,500 | $27.97 |
| Aug 10, 2026 | Ivan Hyep | Sale | 12,500 | $27.97 |
BCAX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-137.95M | -2.52 | $-106.83M |
| Dec 31, 2024 | — | $-68.00M | -4.05 | $-74.75M |
| Dec 31, 2023 | — | $-51.98M | -89.61 | $-45.63M |
Latest balance sheet: total assets $512.24M, total liabilities $43.48M, cash $96.60M (as of Jun 30, 2026).
BCAX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $23.76 |
| May 11, 2026 | 8-K Item 2.02 (results) | $22.92 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $19.04 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $16.80 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $13.93 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $10.47 |
| May 13, 2025 | 8-K Item 2.02 (results) | $13.04 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $13.40 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $22.35 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BCAX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.